GlaxoSmithKline ( GSK.US ) A new long-acting monoclonal antibody drug and new indication have been approved for launch in China.

LootboxPhobia · 2026-04-03T08:36:49+00:00

On April 3rd, GlaxoSmithKline's Demogicumab received approval for a new indication to treat chronic sinusitis with nasal polyps. This drug is the world's first long-acting IL-5 biologic administered once every six months and is expected to become a new favorite in the market.

LootboxPhobia

2026-04-03 08:36:49

Abstract generation in progress

Zhitong Finance APP learned that on April 3, the NMPA website showed that GlaxoSmithKline (GSK.US) “demoskiumab” new indication was approved for launch, for the treatment of chronic rhinosinusitis with nasal polyps.

Screenshot source: NMPA website

Demokimab (Depemokimab) is a next-generation anti–interleukin-5 (IL-5) monoclonal antibody developed by GSK. It has a long half-life, high binding affinity, and high potency. It is the world’s first semiannual ultra–long-acting IL-5 biologic. In December 2025, demokimab became the first global batch to arrive in the United States, indicated for the treatment of eosinophilic asthma. In March 2026, demokimab made its first entry into the China market. This marks the 2nd approved indication for demokimab in China.

GSK has strong capabilities and an industry-leading respiratory product pipeline. The approved demokimab is precisely the iterated product of the once-monthly IL-5 monoclonal antibody “mepolizumab” (new-caller®), and is expected to take over this year’s blockbuster with annual revenue of $2.65B in 2025, becoming the next market hegemon.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.